Fact based stock research
Huaren Pharmaceutical (SZSE:300110)
CNE100000SW1
Due to the geopolitical instabilities, research on companies located in authoritarian regimes has been discontinued. Research at Obermatt is limited to companies in democracies as measured by The Economist Intelligence Unit Democracy Index.
Huaren Pharmaceutical stock research in summary
There is no stock research analysis by the purely financial fact-based Obermatt method for: Huaren Pharmaceutical (SZSE:300110), Pharmaceuticals, China. Contact us if you would like research on this stock.
Latest Obermatt Ranks
| Value Rank | n/a |  |
| Growth Rank | n/a | |
| Safety Rank | n/a | |
| Combined Rank | n/a | |
| Country | China |
| Industry | Pharmaceuticals |
| Index | |
| Size class | Small |
December 31, 2020. Stock data may be delayed. Login to get the most recent research.
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Huaren Pharmaceutical from December 31, 2020.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.